Introduction
============

Lung cancer, also known as primary bronchogenic carcinoma of the lung, is a common malignancy, the incidence of which has increased rapidly in previous years in China ([@b1-mmr-21-01-0051]). Data published by the National Central Cancer Registry of China in 2014 showed 605,900 new cases of lung cancer in China, the highest of all malignant tumors; \~66% of the patients were diagnosed too late for radical surgery ([@b2-mmr-21-01-0051],[@b3-mmr-21-01-0051]). Of those diagnosed too late, the 5-year survival rate of patients with small cell lung cancer (SCLC), accounting for 15--17% of all lung cancers, was only 6%; however, the median 5-year survival rate for limited-stage SCLC was 28--60% ([@b4-mmr-21-01-0051]). Thus, early diagnosis is clearly essential for reducing SCLC mortality. Many patients undergo a delayed examination and further treatment because they exhibit no specific symptoms. Currently, traditional medical diagnosis primarily relies on imaging examinations ([@b5-mmr-21-01-0051]); however, the number of potentially transformed cell clones in patients with early-stage lung cancer is lower than the minimum threshold of current imaging and measurement technology. Therefore, searching for sensitive and specific diagnostic methods applicable even before imaging is necessary to increase the rate of early lung cancer diagnosis.

Cancer proteomics is the study of cancer from the perspective of protein and peptide fragments, and has great potential for early cancer diagnosis. In recent years, mass spectrometry (MS) of proteins and peptides has been increasingly applied to exploratory studies on the early diagnosis of breast, stomach and colon cancers, and other malignancies ([@b6-mmr-21-01-0051]--[@b8-mmr-21-01-0051]). The present study employed matrix-assisted laser desorption/ionization time-of-flight (MALDI-TOF)-MS and nanomagnetic beads to extract serum peptides in combination with the ClinProt system to conduct an exploratory analysis of the sera and urine of patients with SCLC and healthy individuals, and screen for differentially expressed peptides for establishing a foundation for the SCLC serum and urine mass spectrometric diagnostic method. To the best of our knowledge, this is the first exploratory study to identify small cell lung cancer by blood and urine using MALDI-TOF-MS.

Materials and methods
=====================

### Sample source and collection

In total, 155 patients with SCLC at the Department of Lung Cancer of The Fifth Medical Centre, Chinese PLA General Hospital, between October 2014 and April 2016, but only 72 patients with SCLC were enrolled into the study according to the admission criteria, with a median age of 58 (range, 36--83) years and a male:female ratio of 1:1.54. Enrolled patients fulfilled the following criteria: i) Histopathologically or cytologically confirmed as a patient with small cell lung carcinoma \[Extensive Disease (ED) or Limited Disease (LD) stage\] ([@b9-mmr-21-01-0051]); ii) aged 18 years or older; iii) Eastern Cooperative Oncology Group Performance Status score ([@b9-mmr-21-01-0051]) \<2; and, iv) had not previously undergone chemotherapy, radiotherapy, targeted therapy or other cancer treatments. Over the corresponding period, 72 serum and urine samples were collected from healthy individuals who underwent a physical examination at the hospital and were age- and sex-matched with the patients. The median age was 56 (range, 31--72) years and the male:female ratio 1:1.32. These healthy individuals were selected after fulfilling the following criteria: Older than 18 years, and without pulmonary nodules, pneumonia, tuberculosis, or other abnormalities. This study was approved by the Ethics Committee of The Fifth Medical Centre, Chinese PLA General Hospital (no. 2012-11-171). All patients provided written informed consent before undergoing any treatment, or serum or urine sampling. The study overview is shown in [Fig. S1](#SD1-mmr-21-01-0051){ref-type="supplementary-material"} and basic information regarding the characteristics of patients and healthy subjects is presented in [Table I](#tI-mmr-21-01-0051){ref-type="table"}.

### Serum (urine) sampling procedure

During fasting, 3 ml of peripheral venous whole blood (15 ml of midstream urine) was collected at 8:00 am in a test tube containing EDTA anticoagulant (urine collection tube). Samples were maintained at 21°C for 2 h, then centrifuged at 2,500 × g for 10 min at 4°C. The supernatant (serum or urine) was collected, divided into 150 µl aliquots, and stored in a freezer at −80°C.

### Reagents and instrumentation

The following reagents and equipment were used in the present study: Trifluoroacetic acid (TFA, Sigma-Aldrich; Merck KGaA); acetonitrile (ACN; Thermo Fisher Scientific, Inc.); α-Cyano-4-hydroxycinnamic acid (HCCA) and peptide mixture (Bruker Corporation); copper ion-chelating nanomagnetic beads and buffer system (National Center of Biomedical Analysis, Beijing, China); MALDI-TOF-MS instrument (Ultraflex; Bruker Corporation); magnetic bead separator (Bruker Corporation); 3K15 refrigerated benchtop centrifuge (Sigma-Aldrich; Merck KGaA); MTP Anchorchip targets (Var/384; Bruker Corporation); and ClinProTools version 3.0 analytical software (CPT; Bruker Corporation).

### Sample preparation and mass analysis (peptide profiling)

Serum and urine samples from 72 patients with SCLC and 72 healthy individuals were randomly divided into two groups in a 3:1 ratio as follows: A training set comprising samples from 54 patients with SCLC (lung cancer serum group I), 54 patients with SCLC (lung cancer urine group I), 54 healthy individuals (healthy serum group I), and 54 healthy individuals (healthy urine group I) was used to construct the classification model, and a testing set comprising samples from 18 patients with SCLC (lung cancer serum group II), 18 patients with SCLC (lung cancer urine group II), 18 healthy individuals (healthy serum group II), and 18 healthy individuals (healthy urine group II) was used to validate the model. No statistically significant difference in age, sex, smoking status, histological type, or clinical stage was observed between the patients in the training and testing groups. The clinical and pathological characteristics of all patients are listed in [Table I](#tI-mmr-21-01-0051){ref-type="table"}. Bead suspension was retrieved from a 4°C refrigerator, and inverted repeatedly to evenly resuspend the solution. To the 200-µl sample tubes, 7 µl of solid-phase extraction (SPE)-CM magnetic bead suspension, 10 µl of serum, and 95 µl of SPE-CB (Beijing Bioyong Technology Co., Ltd.) were added, and triturated several times to thoroughly mix the magnetic beads, SPE-CB and serum. The mixture was maintained at 21°C for 5 min. Samples were placed in the magnetic bead separator for 1 min to separate the magnetic beads from the solution. After the liquid became clear, the remaining liquid was removed. Samples were removed from the magnetic bead separator and 100 µl of SPE-CW (Beijing Bioyong Technology Co., Ltd.) was added to the sample, and triturated several times to mix the magnetic beads and SPE-CW thoroughly. The mixture was held at 21°C for 2 min. Samples were placed in the magnetic bead separator for 1 min to separate the magnetic beads from the solution. When the liquid became clear, the remaining liquid was removed. The abovementioned step was repeated twice. Then, 10 µl of SPE-CE (Bioyong Tech) was added to each sample tube, and triturated 10 times to mix the magnetic beads and SPE-CE thoroughly. The mixture was held at 21°C for 5 min. Samples were placed in the magnetic bead separator for 1 min to separate the magnetic beads from the solution. When the liquid became clear, it was transferred to a dry sample tube, and stored in a freezer at −20°C for MS analysis.

### Targeting

Saturated HCCA, 0.1% TFA and 50% ACN were mixed in an Eppendorf tube to form the matrix solution. The standard peptide mixture (polypeptide mixture) was mixed thoroughly in a 2:1 ratio. For external instrument calibration, 1 µl of this sample was used. Next, 1 µl of each sample after magnetic bead processing and 1 µl of the prepared matrix solution were mixed thoroughly in a 1:1 ratio. Then, 1 µl of this sample was placed on an MTP Anchorchip target, and allowed to air-dry at 21°C.

### MS analysis

After extracting serum peptides from the SPE-CM magnetic beads, linear mode detection via MALDI-TOF-MS was performed. After targeting, the MTP Anchorchip target was placed in a MALDI-TOF mass spectrometer for analysis. To reduce operational error and systematic error, one standard target (standardized peptide mixture) was used for each sample group, before analysis, as an external sample for external instrument calibration. The best scanning mass-to-charge ratio (m/z) range for MALDI-TOF-MS is 0.8--10 kDa. Each scan accumulated 500 mass spectrum signals, and each sample accumulated 3,000 signals. The accumulated spectra were saved, thereby generating an accurate serum peptide mass fingerprint map comprising peptide peaks with different m/z ratios.

### Data collection and preservation

The datasets generated and/or analyzed during the current study are available in a repository hosted by Mendeley at the following link: <http://dx.doi.org/10.17632/btg4dknchy.1>, which includes the 'final upload data for this experiment', and whether the data uploaded onto Mendeley was used to establish the prediction models or validate the classification model, as well as its stability and reliability ([@b10-mmr-21-01-0051]).

### Statistical analysis

CPT software was used for the statistical analysis of all mass spectral data obtained. Before complete analysis using CPT, the original mass spectra of the samples were processed, including baseline correction, alignment and normalization using CPT. Next, the statistical analysis of the serum peptide spectra of the 54 patients with SCLC and 54 healthy individuals composing the training group was conducted using the statistical algorithms included in CPT. The peptides differentially expressed between the two groups were obtained; three algorithms \[genetic algorithm (GA), supervised neural networks and quick classifier\], which components of the CPT, were used to establish the prediction models.

Similarly, the statistical analysis of urine peptides revealed the urine peptides differentially expressed between the 54 patients with SCLC and 54 healthy individuals in the training group, and a urine classification model for SCLC diagnosis was constructed from a number of peptides selected by CPT. The categorical variables were analyzed using the χ^2^ test; GA was used to identify differentially expressed peptides between the 54 SCLC patients and 54 healthy controls; Cross Tabulations analysis was used for sensitivity and specificity; at the same time, the plasma and urine classification models were combined to verify the specificity and sensitivity of their combinations. κ test was used to perform consistency analysis. All statistical tests were two-tailed, and a P-value of \<0.0005 was considered statistically significant. All statistical tests were performed using SPSS software (version 19; IBM Corp.).

Results
=======

### Serum peptide mass fingerprinting map for training set

[Fig. 1](#f1-mmr-21-01-0051){ref-type="fig"} shows the serum peptide mass fingerprinting maps of lung cancer serum group I and healthy serum group I obtained by performing MALDI-TOF-MS to detect serum peptides in the training set extracted using the magnetic beads for the 54 patients with SCLC and 54 healthy individuals, respectively, in the training group.

### Analysis of differentially expressed peptides in serum samples of training set

The serum peptide mass fingerprinting maps of lung cancer serum group I and healthy serum group I were analyzed using CPT, which identified 126 peptide peaks in total; 19 peaks were significantly different (P\<0.0005; AUC≥0.8) between the 2 groups ([Table II](#tII-mmr-21-01-0051){ref-type="table"}).

The clustering analytical method of CPT ([Fig. 1C](#f1-mmr-21-01-0051){ref-type="fig"}) was used for comparison analysis of the serum peptide mass fingerprinting maps of lung cancer serum group I and healthy serum group I, and GAs were obtained. The result of this algorithm showed that the optimal template comprised 5 peptides whose m/z peptide peaks were at 0.8114, 0.83425, 1.86655, 4.11133 and 5.81192 kDa ([Fig. 2](#f2-mmr-21-01-0051){ref-type="fig"}). The resulting model had a lung cancer detection rate of 99.04% and cross-validation rate of 91.47%.

For the sera of the 18 patients with lung cancer and 18 healthy individuals in the testing set, the serum peptide mass fingerprinting map was similarly obtained using CPT, and the model constructed using GA was validated. The 18 patients with lung cancer and 18 healthy individuals were accurately identified (1 false negative among the 18 patients with lung cancer, 2 false positives among the 18 healthy individuals; the others were correctly identified). Blinded validation showed that the model had a specificity of 90% and sensitivity of 95%.

### Analysis of differentially expressed peptides in urine samples of training set

[Fig. 3](#f3-mmr-21-01-0051){ref-type="fig"} shows the urine peptide mass fingerprinting maps of lung cancer urine group I and healthy urine group I, obtained using MALDI-TOF-MS to detect urine peptides in the training set extracted from the magnetic beads for the 54 patients with SCLC and 54 healthy individuals in the training group.

The urine peptide mass fingerprinting maps of lung cancer urine group I and healthy urine group I were analyzed using CPT, which identified 132 peptide peaks in total; 8 peaks were significantly different (P\<0.0005; AUC≥0.8) between the two groups ([Table III](#tIII-mmr-21-01-0051){ref-type="table"}).

The clustering analytical method of CPT ([Fig. 3C](#f3-mmr-21-01-0051){ref-type="fig"}) was used for comparison analysis of the urine peptide mass fingerprinting maps of lung cancer urine group I and healthy urine group I, and GAs were obtained. The result of this algorithm showed that the optimal template comprised 5 peptides whose m/z peptide peaks were at 1.0724, 2.37692, 2.7554, 4.75475 and 4.7949 kDa ([Fig. 4](#f4-mmr-21-01-0051){ref-type="fig"}). The resulting model had a lung cancer detection rate of 87.81% and cross-validation rate of 79.49%.

For the urine samples of the 18 patients with lung cancer and 18 healthy individuals in the testing set, the urine peptide mass fingerprinting map was similarly obtained using CPT, and the model constructed using GA was validated. The 18 patients with lung cancer and 18 healthy individuals were accurately identified (2 false negatives among the 18 patients with lung cancer, 4 false positives among the 18 healthy individuals; the others were correctly identified). Blinded validation showed that the model had a specificity of 80% and a sensitivity of 90%.

### Peptide peak identification

To further study the specific peptide peaks for serum and urine, 3 peptide peaks with simultaneously upregulated expression in the sera and urine of the patients with SCLC were examined. Their m/z ratios were 2.3764, 0.8778 and 0.8616 kDa. A search of the liquid chromatography/MS secondary mass spectrum database of our laboratory determined the 2.3764-kDa peptide peak to correspond to fibrinogen α, having the sequence SYK MAD EAG SEA DHE GTH STK RGH AKS RPV, the 0.8778-kDa peptide peak to correspond to glucose-6-phosphate isomerase, having the sequence RNG FKS HAL QLN NRQ I, and the 0.8616-kDa peptide peak to correspond to cyclin-dependent kinase-1, having the sequence SSK ITH RIH WES ASL LR.

### Consistency analysis of serum model and urine model blind sample verification results

The results of the blind test results of the serum model and the urine model were further analyzed. It was found that in 18 patients with lung cancer and 18 healthy individuals, in the serum model, 1 patient with lung cancer was false negative, and this patient gave the same result in the urine model. Of the 2 patients who showed false positive results, 1 was still a false positive in the urine model, and the other was diagnosed correctly to be a healthy individual. The remaining patients showing false positive or false negative results in the urine model were diagnosed correctly in the serum model. It can be seen that the sensitivity and specificity of the serum model are higher than those of the urine model, and the serum model is in good agreement with the urine model (κ=0.720; P\<0.001). The results of the blind sample verification results are shown in [Table IV](#tIV-mmr-21-01-0051){ref-type="table"}.

Discussion
==========

Mass spectrometry analysis is an important detection method in cancer proteomics. Currently, the mass spectrometric techniques common in biology include MALDI-TOF-MS, electrospray ionization (ESI)-MS, and surface-enhanced laser desorption/ionization (SELDI)-TOF-MS. High tolerance to salt and impurities and high sensitivity render MALDI-TOF-MS superior to other MS techniques ([@b11-mmr-21-01-0051]). After reflective and delayed extraction techniques were introduced for the method, the resolution of the method increased greatly, reaching ≤10 ppm for detecting small molecular peptides of \~2 kDa ([@b12-mmr-21-01-0051],[@b13-mmr-21-01-0051]).

Considering the high sensitivity, high throughput and other advantages of MS for protein identification, numerous studies have attempted to use MS detection for early-stage cancer diagnosis, primarily via MS analysis of samples from patients with cancer and healthy individuals, thereby discovering differentially expressed cancer-specific proteins or peptides. For example, Monari *et al* ([@b14-mmr-21-01-0051]) used IMAC30-Cu and H50 SELDI-TOF-MS chips to study 44 patients with lung cancer and 19 healthy individuals; the study observed 28 significantly different peaks and constructed a model. The sensitivity and specificity of the IMAC30-Cu chip were 70.45 and 68.42%, respectively, and the sensitivity and specificity of the H50 chip were 72.73 and 73.68%, respectively. Han *et al* ([@b15-mmr-21-01-0051]) used metal affinity protein chips and SELDI-TOF technology to study serum samples and used 3 proteins to construct a classification tree model. Blinded validation revealed a sensitivity of 89%, specificity of 91%, and accuracy of 90%. Hocker *et al* ([@b16-mmr-21-01-0051]) used ESI-MS to analyze serum samples of 43 patients with early-stage lung cancer and 21 healthy individuals, and the method using the differentially expressed proteins identified for differentiating between the cancer patients and healthy individuals had an overall efficacy of 80% and sensitivity of 84%. Results from these studies demonstrate that MS detection methods can recognize cancer-related molecules contained in the sera of patients with lung cancer, and can potentially be used for early lung cancer diagnosis.

However, the sensitivity and specificity of blinded validation in the aforementioned studies were relatively low, with no further validation being subsequently performed for the following reasons: i) All traditional methods for extracting proteins and peptides from samples, including pre-processing techniques, such as 2-dimensional gel electrophoresis, protein chip-based methods, or solid phase extraction, have operational complexities and low extraction efficiencies, resulting in the loss of usable information; and ii) ESI, SELDI-TOF-MS, and other mass spectrometric detection methods have low sensitivity and resolution, and reflect limited information. These limitations have restricted their application in disease-specific marker discovery and clinical diagnosis. Hence, the present study used the CPT detection system developed by Bruker Daltonics ([@b17-mmr-21-01-0051]). It includes a magnetic bead separation system, a MALDI-TOF-MS system, analytical software and automated body fluid sample processing system. Its advantages are that it contains the latest Anchor-Chip patented sample targeting technology, which can greatly increase the analyte concentration, and increase sensitivity to 10--100 times that of conventional chips, and the resolution, repeatability and reproducibility of MALDI-TOF-MS are higher than those of SELDI-TOF and other mass spectrometric techniques ([@b18-mmr-21-01-0051]). At various world-class hospitals and medical research institutes, this technology has been widely used in studies on the early diagnosis of ovarian cancer, lung adenocarcinoma and multiple myeloma patients ([@b19-mmr-21-01-0051]--[@b21-mmr-21-01-0051]).

The present study used the CPT detection system for the sera and urine of patients with SCLC and healthy individuals, and discovered 19 differentially expressed peptides in serum and 8 differentially expressed peptides in urine. Next, the statistical software screened 5 peptide peaks for constructing the serum and urine SCLC diagnostic classification models. Blinded model validation was performed, and satisfactory results were obtained, demonstrating that the classification model of the present study had a certain theoretical value for identifying patients with SCLC, although it still requires further clinical validation. The classification model of the present study was unlike traditional diagnostic models based on a single index for detection; rather, it used a group of peptide indicators as detection criteria. It used biological mass spectrometry as the support platform, and bioinformatics as the bridge for peptide research, and via changes in the blood peptidome of patients with lung cancer, specific cancer-related information could be obtained to establish cancer diagnosis. When blood flows through the tumor microenvironment, it may cause various slight changes in unknown components of serum proteins/peptides, making the use of markers in combination more effective than the use of a single marker. In the present study, the statistically significantly differentially expressed proteins observed in both serum and urine were fibrinogen α, glucose-6-phosphate isomerase and cyclin-dependent kinase-1. Fibrinogen is a protein with coagulant activity synthesized by the liver; a number of studies have shown that fibrinogen is upregulated in cancers of the urinary system, reproductive system and gastrointestinal tract ([@b22-mmr-21-01-0051]--[@b24-mmr-21-01-0051]).

The present study identified high fibrinogen α expression in the sera and urine of patients with SCLC, which may be associated with the hypercoagulable state of patients with cancer. Glucose-6-phosphate isomerase is an important enzyme in humans. The main function is to catalyze the exchange between D-glucose-6-phosphate and D-fructose-6-phosphate, which is an important enzyme for glycolysis and gluconeogenesis. Although there are no reports on its involvement in cancer development and progression, to the best of the authors\' knowledge. Cyclin-dependent kinase 1 is a protein kinase family member, and depends on binding with cell cycle proteins to serve key roles in the systematic progress of the cell cycle. When cell cycle proteins are lacking, or cyclin-dependent kinase inhibitors are present, cell division is arrested and cell death may occur ([@b25-mmr-21-01-0051]). Future studies will employ ELISA to validate the expression of the three peptides identified in the serum and urine samples of the patients with SCLC. The majority of SCLC cases are already in LD stages when discovered (there were only 5 ED patients in the present study). The model has been established and validated in patients with LD SCLC, but whether this model can be used for ED SCLC patient diagnosis remains to be verified. The future aims of this study are to increase the number of LD SCLC samples used, validate the reproducibility and reliability of the diagnostic classification model, further identify the peptides corresponding to the m/z peaks, and evaluate protein/peptide expression, to identify novel tumor markers of lung cancer, and study their associations with the molecular mechanisms of lung cancer development.

The use of the specific serum and urine peptide-spectrum model for SCLC was revealed to be accurate in a small cohort of patients. In the future, a large-scale validation with actual clinical operation should be conducted, and it is expected to create the foundation for developing a serum- and urine-based diagnosis that is rapid, non-invasive and requires a small sample quantity.

The present study selected the sera and urine of patients with SCLC and healthy individuals as the research subjects, used MALDI-TOF-MS with the CPT system to detect serum and urine peptides, performed small-scale validation of specific SCLC-related peptides, and achieved high sensitivity and specificity, as the samples originated primarily from LD-stage patients. Samples from more ED-stage patients, as well as dynamic monitoring of samples from high-risk populations, should be included in future studies, to further validate the sensitivity and specificity of this diagnostic model.
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###### 

Basic information on the characteristics of patients with SCLC and healthy subjects.

  A, Training group (n=108)                                                       
  ----------------------------- ----------------- ------------------------------- -------------
  Age (years)                                                                     0.894
    Median                      59                56                              
    Range                       36--83            31--72                          
  Sex                                                                             0.774
    Male                        33                32                              
    Female                      21                22                              
  Ever smoked                                                                     0.482
    Yes                         28                24                              
    No                          26                30                              
  Staging                                                                         --
    LD                          5                 --                              
    ED                          49                --                              
                                                                                  
  **B, Testing group (n=36)**                                                     
                                                                                  
  **Characteristics**           **SCLC (n=18)**   **Healthy individual (n=18)**   **P-value**
                                                                                  
  Age (years)                                                                     0.673
    Median                      57                55                              
    Range                       42--74            35--68                          
  Sex                                                                             0.916
    Male                        10                9                               
    Female                      8                 9                               
  Ever smoked                                                                     0.910
    Yes                         10                8                               
    No                          8                 10                              
  Staging                                                                         --
    LD                          0                 --                              
    ED                          18                --                              

SCLC, small cell lung cancer; LD, limited disease; ED, extensive disease.

###### 

Differential peaks in serum from the patients with SCLC compared with healthy individuals in the training group.

  m/z (Da)   Peak areas of the healthy group I (X±S)   Peak areas of the SCLC group I (X±S)   Peak areas in patients with SCLC compared with the healthy individuals   P-value
  ---------- ----------------------------------------- -------------------------------------- ------------------------------------------------------------------------ ----------
  1,866.37   24.8±17.7                                 2.85±1.61                              ↓                                                                        \<0.0005
  1,779.22   7.7±5.4                                   1.19±0.59                              ↓                                                                        \<0.0005
  1,692.13   3.47±2.21                                 0.77±0.33                              ↓                                                                        \<0.0005
  3,541.28   5.56±3.18                                 2.61±1.46                              ↓                                                                        \<0.0005
  5,251.47   0.5±0.18                                  0.87±0.32                              ↑                                                                        \<0.0005
  2,210.62   13.3±9.48                                 4.03±4.15                              ↓                                                                        \<0.0005
  2,366.84   4.26±2.86                                 1.45±1                                 ↓                                                                        \<0.0005
  1,968.41   1.94±0.69                                 1.28±0.34                              ↓                                                                        \<0.0005
  8,952.22   8.37±6.19                                 16.59±9.9                              ↑                                                                        \<0.0005
  4,055.64   3.66±2.07                                 9.41±6.81                              ↑                                                                        \<0.0005
  2,082.49   8.75±6.06                                 3.56±2.34                              ↓                                                                        \<0.0005
  3,444.06   1.8±0.84                                  2.96±1.44                              ↑                                                                        \<0.0005
  839.2      4.38±1.87                                 2.47±1.4                               ↓                                                                        \<0.0005
  1,450.69   2.61±1.8                                  1.1±0.55                               ↓                                                                        \<0.0005
  1,980.53   2.46±0.96                                 1.47±0.55                              ↓                                                                        \<0.0005
  1,011.84   2.53±1.7                                  0.98±0.67                              ↓                                                                        \<0.0005
  1,887.67   2.68±1.47                                 1.44±1.1                               ↓                                                                        \<0.0005
  1,882.02   2.56±1.81                                 1.04±0.89                              ↓                                                                        \<0.0005
  4,111.85   1.45±0.53                                 2.33±1.09                              ↑                                                                        \<0.0005

SCLC, small cell lung cancer; ↑, signals with a higher peak area in the SCLC group; ↓, signals with a lower peak area in the SCLC group.

###### 

Differential peaks in urine from the patients with SCLC compared with healthy individuals in the training group.

  m/z (Da)   Peak areas of the healthy group I (X±S)   Peak areas of the SCLC group I (X±S)   Peak areas in SCLC patients compared with the healthy individuals   P-value
  ---------- ----------------------------------------- -------------------------------------- ------------------------------------------------------------------- ----------
  4,754.75   0.5±0.18                                  0.87±0.32                              ↓                                                                   \<0.0005
  2,376.92   4.26±2.86                                 1.45±1.00                              ↓                                                                   \<0.0005
  4,794.90   0.61±0.19                                 0.85±0.26                              ↓                                                                   \<0.0005
  4,712.28   1.8±0.84                                  2.96±1.44                              ↓                                                                   \<0.0005
  4,625.74   9.98±3.28                                 7.45±2.76                              ↓                                                                   \<0.0005
  4,900.42   2±0.92                                    4.47±4.54                              ↓                                                                   \<0.0005
  6,341.19   5.95±2.33                                 3.6±1.8                                ↑                                                                   \<0.0005
  2,755.40   2.93±1.25                                 1.9±0.95                               ↓                                                                   \<0.0005

SCLC, small cell lung cancer; ↑, signals with a higher peak area in the SCLC group; ↓, signals with a lower peak area in the SCLC group.

###### 

Consistency analysis of serum model and urine model blind sample verification results.

            Serum model                     
  --------- ------------- ---- ---- ------- ---------
  SCLC      16            4    20   0.720   \<0.001
  Healthy   3             13   16           
  Total     19            17   36           

SCLC, small cell lung cancer.
